For clinicians · latest clinical updates

Women’s heart health. The evidence behind the updates.

Clinical updates with original sources, study limitations and implications for care.

September 4, 2026 · Lp(a) · Outcomes trial

Preliminary topline: pelacarsen did not meet its primary endpoint

What changed?

In a company announcement—not yet a peer-reviewed trial report—Novartis said pelacarsen lowered Lp(a) but did not significantly reduce the primary composite cardiovascular endpoint in the overall trial population.

What does the evidence actually show?

Lowering a biomarker is not, by itself, proof that a treatment improves clinical outcomes. Full peer-reviewed results and subgroup analyses are needed to understand the finding.

What does it not show?

This does not erase the observational and genetic evidence that elevated Lp(a) can mark higher cardiovascular risk. It also does not establish outcome benefit for pelacarsen.

Current practice context

Current guideline-based prevention still treats Lp(a) as a risk-enhancing factor. This company announcement does not support presenting pelacarsen as an established outcome-improving therapy.

What should we watch next?

Peer-reviewed trial publication, prespecified subgroup results, safety data, and outcomes from other Lp(a)-lowering programs.

Source: Novartis topline results (opens in a new tab)

March 13, 2026 · Prevention · Dyslipidemia

The 2026 ACC/AHA dyslipidemia guideline expands risk refinement

What changed?

The updated guideline emphasizes earlier prevention, recommends Lp(a) measurement at least once in adulthood, supports selective ApoB use, and gives coronary calcium a role in selected uncertain decisions.

What does the evidence actually show?

Risk assessment can extend beyond LDL-C alone when family history, metabolic context, inherited risk, or uncertainty changes the question.

What does it not show?

It does not make every advanced test appropriate for every patient, and no single biomarker or scan replaces the clinical picture.

Current practice context

The guideline supports reviewing lifetime exposure and risk enhancers, then considering additional testing when the result is reasonably likely to change a decision. Lp(a) is largely inherited and one measurement is often sufficient. Consider a repeat when an earlier result was intermediate and it could change risk assessment, including after menopause or pregnancy or with chronic kidney disease or hypothyroidism. This is not routine repeat testing for every woman at menopause. When Lp(a) is high, ask about testing parents, siblings and children.

What should we watch next?

Implementation details, patient access, and how newer evidence changes treatment thresholds over time.

Source: ACC/AHA guideline (opens in a new tab)

February 12, 2026 · Menopause · Regulation

FDA approved labeling changes for initial menopausal hormone therapy products

What changed?

FDA approved revised labeling for a first group of six products, removing cardiovascular disease, breast cancer, and probable dementia risk statements from those products’ boxed warnings. Relevant cardiovascular and breast-cancer safety information remains elsewhere in labeling, and systemic estrogen-alone products retain an endometrial-cancer boxed warning.

What does the evidence actually show?

Label language and the evidence conversation have changed. Treatment decisions still depend on the product, route, timing, symptoms, contraindications, and individual history.

What does it not show?

The action does not make hormone therapy risk-free, appropriate for everyone, or a treatment to prevent cardiovascular disease.

Current practice context

The FDA action leaves treatment decisions grounded in current labeling, the woman’s goals and history, and shared decision-making. It does not create a universal recommendation.

What should we watch next?

Additional product-label revisions and specialty-society implementation guidance.

Source: U.S. Food and Drug Administration (opens in a new tab)

March 29, 2025 · INOCA · Trial results

WARRIOR: intensive medical therapy did not significantly reduce the primary outcome

What changed?

In women with suspected ischemia and no obstructive coronary artery disease, the pragmatic WARRIOR trial did not show a statistically significant reduction in its primary composite outcome with the intensive strategy tested.

What does the evidence actually show?

The result underscores the difficulty of translating a heterogeneous INOCA population into one uniform treatment strategy and the need to define mechanism and phenotype carefully.

What does it not show?

It does not show that persistent symptoms are unreal, that INOCA is unimportant, or that individualized risk-factor care and symptom evaluation should stop.

Current practice context

The trial summary supports avoiding claims about one universal regimen while keeping evaluation, symptom care, and prevention tied to the full clinical context.

What should we watch next?

Complete publication, phenotype-specific analyses, adherence and crossover effects, and trials that match treatment to coronary mechanism.

Source: American College of Cardiology trial summary (opens in a new tab)

April 12, 2024 · Pregnancy history · Prevention

Postpartum care is a bridge to long-term cardiovascular prevention

What changed?

The AHA scientific statement consolidated practical approaches to cardiovascular risk reduction after adverse pregnancy outcomes.

What does the evidence actually show?

Hypertensive disorders of pregnancy, gestational diabetes, preterm delivery, placental abruption, and fetal growth restriction are associated with later cardiovascular risk and warrant durable history-taking and follow-up.

What does it not show?

An association is not destiny. The evidence does not mean every pregnancy experience independently predicts maternal cardiovascular disease or mandates the same testing pathway.

Current practice context

The scientific statement supports asking about, documenting, and carrying recognized adverse pregnancy outcomes forward alongside current blood pressure, cholesterol, blood sugar, symptoms, family history, and care context.

What should we watch next?

Implementation research on record portability, equitable follow-up, and effective transitions from obstetric to primary and cardiovascular care.

Source: American Heart Association scientific statement (opens in a new tab)

See something that needs correction?

Focused review is welcome.

Identify the exact statement and the best primary source. Review is not presented as endorsement.

Send a focused correction